The Enterprise DG of the European Commission retained Charles River Associates to undertake a study investigating whether there is a worldwide crisis in innovation in the pharmaceutical sector, the reasons behind this crisis, and the tools available to kick-start innovation.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...